These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39418110)

  • 1. Single-Dose Physically Cross-Linked Hyaluronic Acid and Lipid Hybrid Nanoparticles Containing Cyclic Guanosine Monophosphate-Adenosine Monophosphate Eliminate Established Tumors.
    Yu J; Li X; Li J; Sun N; Cheng P; Huang J; Li S; Kuai R
    ACS Nano; 2024 Oct; 18(43):29942-29955. PubMed ID: 39418110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth.
    Shaji SG; Patel P; Mamani UF; Guo Y; Koirala S; Lin CY; Alahmari M; Omoscharka E; Cheng K
    Int J Nanomedicine; 2024; 19():8769-8778. PubMed ID: 39220196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages.
    Lee E; Jang HE; Kang YY; Kim J; Ahn JH; Mok H
    Acta Biomater; 2016 Jan; 29():271-281. PubMed ID: 26485167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
    Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
    Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.
    Koshy ST; Cheung AS; Gu L; Graveline AR; Mooney DJ
    Adv Biosyst; 2017 Feb; 1(1-2):. PubMed ID: 30258983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
    Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
    Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytosolic Delivery of Thiolated Mn-cGAMP Nanovaccine to Enhance the Antitumor Immune Responses.
    Chen C; Tong Y; Zheng Y; Shi Y; Chen Z; Li J; Liu X; Zhang D; Yang H
    Small; 2021 Apr; 17(17):e2006970. PubMed ID: 33719177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
    Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
    J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity.
    Bao P; Zheng ZT; Ye JJ; Zhang XZ
    Nano Lett; 2022 Mar; 22(6):2217-2227. PubMed ID: 35254071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
    Liu Y; Crowe WN; Wang L; Lu Y; Petty WJ; Habib AA; Zhao D
    Nat Commun; 2019 Nov; 10(1):5108. PubMed ID: 31704921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.
    Junkins RD; Gallovic MD; Johnson BM; Collier MA; Watkins-Schulz R; Cheng N; David CN; McGee CE; Sempowski GD; Shterev I; McKinnon K; Bachelder EM; Ainslie KM; Ting JP
    J Control Release; 2018 Jan; 270():1-13. PubMed ID: 29170142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy.
    Cheng SL; Lee HM; Li CP; Lin MW; Chou MY; Yen YT; Wu TH; Lian YC; Shih YC; Chiang CS; Chen TW; Wan D; Chen Y
    ACS Nano; 2024 Oct; 18(43):29439-29456. PubMed ID: 39405469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
    Zhou S; Cheng F; Zhang Y; Su T; Zhu G
    Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.
    Chin EN; Yu C; Vartabedian VF; Jia Y; Kumar M; Gamo AM; Vernier W; Ali SH; Kissai M; Lazar DC; Nguyen N; Pereira LE; Benish B; Woods AK; Joseph SB; Chu A; Johnson KA; Sander PN; Martínez-Peña F; Hampton EN; Young TS; Wolan DW; Chatterjee AK; Schultz PG; Petrassi HM; Teijaro JR; Lairson LL
    Science; 2020 Aug; 369(6506):993-999. PubMed ID: 32820126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.